CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
November 09 2018 - 07:00AM
--CRISPR Therapeutics Gains Additional Rights to
MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based
Cell Therapies in Immuno-Oncology--
CRISPR Therapeutics (NASDAQ:CRSP) and MaxCyte today announced the
expansion of their existing relationship by entering into a
non-exclusive commercial license agreement that will allow CRISPR
Therapeutics to deploy MaxCyte’s Flow Electroporation® Technology
to develop CRISPR/Cas9-based therapies in immuno-oncology.
“As we advance our allogeneic CAR-T programs
into the clinic, we are preparing for the future by securing our
access to the leading ex vivo delivery platform for both
clinical and commercial use, just as we previously did for our
hemoglobinopathy developmental candidates,” said Samarth
Kulkarni, CEO of CRISPR Therapeutics.
The expanded relationship builds on an existing
agreement announced in March 2017 which allowed for the development
of commercial therapeutics for hemoglobin-related diseases. Under
the terms of the new license agreement, CRISPR Therapeutics will
obtain non-exclusive development and commercial-use rights to
MaxCyte’s cell engineering platform to develop immuno-oncology cell
therapies. MaxCyte will supply its technology to CRISPR
Therapeutics as part of the enabling technology license agreement
and will receive milestone and sales-based payments in addition to
other licensing fees.
“The expansion of our relationship with CRISPR
Therapeutics signifies a key milestone for MaxCyte and our
technology, providing further validation for the value and
versatility of our technology as a leading enabler of
next-generation cell-based therapies,” said Doug Doerfler,
President & CEO of MaxCyte, Inc. “CRISPR Therapeutics is a
leader in gene editing, and we are very pleased to expand our
collaboration into new therapeutic areas as we continue to explore
the use of our technology to advance medicines to market that will
make a difference for patients.”
MaxCyte’s Flow Electroporation® Technology
enables the engineering of a broad range of
therapeutically-relevant cell types at high efficiency while
maintaining high viability and recovery. CRISPR Therapeutics’
immuno-oncology cell therapy programs rely on ex vivo gene editing,
where the CRISPR components are delivered into T-cells using the
MaxCyte technology.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer AG,
Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR
Therapeutics AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and
R&D operations based in Cambridge, Massachusetts, and business
offices in London, United Kingdom. For more information, please
visit www.crisprtx.com.
About MaxCyteMaxCyte is a
global cell-based medicines and life sciences company applying its
patented cell engineering technology to help patients with high
unmet medical needs in a broad range of conditions. MaxCyte is
developing novel CARMA therapies for its own pipeline. CARMA is
MaxCyte’s mRNA-based proprietary platform for autologous cell
therapy. In addition, through its core business, the Company
leverages its Flow Electroporation® Technology platform to enable
its biopharmaceutical industry partners to advance the development
of innovative, cutting-edge medicines, particularly in cell
therapy, including the use of gene editing tools in the treatment
of inherited genetic diseases and immuno-oncology approaches to
treating cancer. The Company has placed its cutting-edge flow
electroporation instruments worldwide, including with nine of the
top ten global biopharmaceutical companies, and has more than 55
partnered program licenses in cell therapy, including more than 25
licensed for clinical use. With its robust delivery technology,
MaxCyte helps its partners to unlock the full potential of their
products. For more information, visit www.maxcyte.com.
CRISPR Forward-Looking StatementThis press
release may contain a number of “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including statements regarding CRISPR
Therapeutics’ expectations about any or all of the following:
(i) clinical trials (including, without limitation, the timing of
filing of clinical trial applications and INDs, any approvals
thereof and the timing of commencement of clinical trials),
development timelines and discussions with regulatory authorities
related to product candidates under development by CRISPR
Therapeutics and its collaborators; (ii) the number of patients
that will be evaluated, the anticipated date by which enrollment
will be completed and the data that will be generated by ongoing
and planned clinical trials, and the ability to use that data for
the design and initiation of further clinical trials; (iii) the
scope and timing of ongoing and potential future clinical trials;
(iv) the intellectual property coverage and positions of CRISPR
Therapeutics, its licensors and third parties; (v) the sufficiency
of CRISPR Therapeutics’ cash resources; and (vi) the therapeutic
value, development, and commercial potential of CRISPR/Cas9 gene
editing technologies and therapies. Without limiting the
foregoing, the words “believes,” “anticipates,” “plans,” “expects”
and similar expressions are intended to identify forward-looking
statements. You are cautioned that forward-looking statements
are inherently uncertain. Although CRISPR Therapeutics believes
that such statements are based on reasonable assumptions within the
bounds of its knowledge of its business and operations,
forward-looking statements are neither promises nor guarantees and
they are necessarily subject to a high degree of uncertainty and
risk. Actual performance and results may differ materially from
those projected or suggested in the forward-looking statements due
to various risks and uncertainties. These risks and uncertainties
include, among others: the outcomes for each CRISPR
Therapeutics’ planned clinical trials and studies may not be
favorable; that one or more of CRISPR Therapeutics’ internal or
external product candidate programs will not proceed as planned for
technical, scientific or commercial reasons; that future
competitive or other market factors may adversely affect the
commercial potential for CRISPR Therapeutics’ product candidates;
uncertainties inherent in the initiation and completion of
preclinical studies for CRISPR Therapeutics’ product candidates;
availability and timing of results from preclinical studies;
whether results from a preclinical trial will be predictive of
future results of the future trials; uncertainties about regulatory
approvals to conduct trials or to market products; uncertainties
regarding the intellectual property protection for CRISPR
Therapeutics’ technology and intellectual property belonging to
third parties; and those risks and uncertainties described under
the heading "Risk Factors" in CRISPR Therapeutics’ most recent
annual report on Form 10-K, and in any other subsequent filings
made by CRISPR Therapeutics with the U.S. Securities and Exchange
Commission, which are available on the SEC's website at
www.sec.gov. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date they are made. CRISPR Therapeutics
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
CRISPR Investor Contact: Susan Kim
susan.kim@crisprtx.com
CRISPR Media Contact: Jennifer Paganelli WCG on
behalf of CRISPR +1-347-658-8290 jpaganelli@wcgworld.com
|
MaxCyte, Inc.
Contacts:Doug Doerfler, Chief Executive
Officer+1-301-944-1660 |
Media Contact:Jamie
Lacey-MoreiraPressComm PR on behalf of
MaxCyte+1-410-299-3310jamielacey@presscommpr.com |
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Feb 2024 to Mar 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2023 to Mar 2024